NCT03397706 2025-03-20
Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies
Viracta Therapeutics, Inc.
Phase 1/2 Completed
Clinical Trials
3 trialsNCT00093704 2020-07-31
Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma
Jonsson Comprehensive Cancer Center
Phase 1 Terminated
NCT00992732 2011-08-01
Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders
HemaQuest Pharmaceuticals Inc.
Phase 2 Terminated